|Mr. Douglas J. Devine||CFO, Sec. & Interim CEO||573.16k||N/A||1970|
|Mr. Daniel G. Wilson||Exec. VP of Strategy, Corp. Devel. & Investor Relations||517.65k||N/A||N/A|
|Mr. David A. Vort||Exec. VP of Sales||552.1k||28.85M||1966|
|Mr. Mark J. Day Ph.D.||Exec. VP of R&D||538.43k||856.63k||1971|
|Mr. Kevin M. King||Consultant & Director||1.39M||39.16M||1956|
|Ms. Marga Ortigas-Wedekind||Exec. VP of Marketing||N/A||N/A||1962|
|Ms. Kaja J. Odegard||VP of HR||N/A||N/A||1982|
|Ms. Judith C. Lenane||Chief Clinical Officer & Exec. VP of Operations||N/A||N/A||1959|
|Mr. Allan B. Wilsker||Exec. VP of Information Technology & Customer Service||N/A||N/A||1959|
|Mr. Mark Topash||Exec. VP of Payer Relations and Market Access||N/A||N/A||N/A|
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
iRhythm Technologies, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 8.